TABLE 1.

Basic characteristics of the included studies (20–24).

Trial	Drug	Median follow-up duration (years)	Total participants (GLP-1 RAs/Placebo)	Male, n (%)	Median age (years)	Patients with a history of MI, n (%)	NCT number
ELIXA (20)	Lixisenatide	2.1	6,068 (3,034/3,034)	4,207 (69.3%)	60.3	5,014 (82.6%)	NCT01147250
HARMOzNY OUTCOMES (21)	Albiglutide	1.6	9,463 (4,731/4,732)	6,569 (69.4%)	64.1	4,459 (47.1%)	NCT02465515
PIONEER 6 (22)	Semaglutide	1.3	3,183 (1,591/1,592)	2,176 (68.4%)	66.0	1,150 (36.1%)	NCT02692716
SUSTAIN 6 (23)	Semaglutide	2.1	3,297 (1,648/1,649)	2,002 (60.7%)	64.6	1,072 (32.5%)	NCT01720446
LEADER (24)	Liraglutide	3.8	9,340 (4,668/4,672)	6,003 (64.3)	64.3	2,864 (30.7%)	NCT01179048